US EditionMeril Presents Successful LANDMARK RCT One-Year Results at Prestigious EuroPCR 2025
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Meril presents successful LANDMARK RCT one-year results at prestigious EuroPCR 2025
Vapi, 23rd May 2025 – Meril Life Sciences announced one-year results from its pivotal LANDMARK trial, presented during the prestigious Late-Breaking Trial session at EuroPCR 2025, one of the world’s premier cardiology conferences held annually in Paris, France. The LANDMARK trial is the first randomised non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-ex…
Meril Life Sciences [Newsroom]Vapi, India (ots/PRNewswire) - First randomized head-to-head TAVI study of its kind confirms performance and safety of the Next-Gen Myval-THV series Meril Life Sciences today gave the one-year results of its pioneering LANDMARK study ... Continue reading here...Original content of: Meril Life Sciences, transmitted by news aktuell
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
